Your activity: 8 p.v.

Dry eye disease

Dry eye disease
Author:
Roni M Shtein, MD
Section Editor:
Deborah S Jacobs, MD
Deputy Editor:
Jane Givens, MD, MSCE
Literature review current through: Dec 2022. | This topic last updated: Apr 07, 2022.

INTRODUCTION — Dry eye disease (DED) is a multifactorial disease of the ocular surface with loss of homeostasis of the tear film and ocular symptoms. Tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play etiological roles [1]. DED is also known as keratoconjunctivitis sicca, dry eye syndrome, and dysfunctional tear syndrome.

The epidemiology, pathophysiology, clinical presentation, diagnosis, and treatment options for DED will be reviewed here. Various conditions associated with DED are discussed separately. (See "Diagnosis and classification of Sjögren's syndrome" and "Allergic conjunctivitis: Clinical manifestations and diagnosis" and "Blepharitis" and "The red eye: Evaluation and management".)

EPIDEMIOLOGY

Prevalence — In epidemiological studies performed globally, the prevalence of dry eye disease (DED) ranges from 5 to 50 percent [2].

Based on data from the National Health and Wellness Survey, 6.8 percent of the United States adult population (approximately 16.4 million people) have been diagnosed with DED [3]. The prevalence increased with age (2.7 percent in those 18 to 34 years old versus 18.6 percent in those ≥75 years old) and was higher in women than men (8.8 versus 4.5 percent). Prevalence was not affected by education or location of residence.

Risk factors — Risk factors for DED include [4-8]:

Advanced age

Female sex

Hormonal changes (primarily due to decreased androgens)

Systemic diseases (eg, diabetes mellitus, Parkinson disease, Sjögren's syndrome)

Contact lens wear

Systemic medications (antihistamines, anticholinergics, estrogens, isotretinoin, selective serotonin receptor antagonists, amiodarone, nicotinic acid)

Ocular medications (especially those containing preservatives)

Nutritional deficiencies (eg, vitamin A deficiency)

Decreased corneal sensation

Ophthalmic surgery (especially corneal refractive surgery)

Low-humidity environments

Studies of the global burden of DED report that persons living in Asia (principally China, Tibet, Korea) have a higher prevalence [2].

CLINICAL SIGNIFICANCE — Dry eye disease (DED), particularly when severe, can have a significant impact on visual acuity, daily activities, social and physical functioning, and workplace productivity [9-11].

In addition, patients with DED incur direct medical costs through frequent visits to health care professionals as well as pharmacologic and nonpharmacologic therapies. Indirect costs include decreased productivity and time lost from work [12].

PATHOPHYSIOLOGY — Dry eye disease (DED) has a complex and multifactorial etiology. The tear film of the eye consists of aqueous, mucous, and lipid components . A healthy tear film relies on a synergistic interaction of the lacrimal glands, eyelids, and ocular surface, which together comprise the lacrimal functional unit (figure 1) [13]. Dysfunction of any component in the lacrimal functional unit can lead to DED.

Historically, DED has been classified into two general groups: decreased tear production (resulting in aqueous deficient DED) and abnormal meibomian gland physiology (resulting in evaporative DED). However, it is now believed that both mechanisms are present in most patients, although one may be predominant [1]. For all patients, tear film hyperosmolarity and subsequent ocular surface inflammation lead to the variety of symptoms and signs associated with DED.

Symptoms in DED result from activation of sensory nerves of the ocular surface, either due to tear hyperosmolarity, the presence of inflammatory mediators, or hypersensitivity of the sensory nerves [14,15]. (See 'Symptoms' below.)

CAUSES

Decreased tear production — Impaired lacrimal tear production can be caused by any form of lacrimal gland destruction or dysfunction. The reduced volume of aqueous fluid leads to hyperosmolarity of the tear film and subsequently the ocular surface, which incites inflammation of the ocular surface cells [16].

Deficiency of aqueous tear production can be subclassified into two main subtypes:

Sjögren's syndrome – Sjögren's syndrome is a chronic autoimmune inflammatory disorder characterized by diminished lacrimal and salivary gland function with resultant dryness of the eyes and mouth. The onset of Sjögren's syndrome is rare after age 65 years [17]. DED related to Sjögren's syndrome is reviewed separately. (See "Diagnosis and classification of Sjögren's syndrome" and "Clinical manifestations of Sjögren's syndrome: Exocrine gland disease", section on 'Dry eye'.)

Dry eye syndrome not due to Sjögren's syndrome – This syndrome refers to patients with aqueous tear-deficient DED involving lacrimal dysfunction without associated systemic findings. The most common form is age-related DED in which it is believed that there is lacrimal ductal obstruction over time, leading to decreased lacrimal gland function [18]. Lacrimal gland obstruction can also be due to conjunctival scarring conditions such as trachoma, pemphigoid, vitamin deficiency, post-viral syndromes, and ocular burns [19]. (See "Trachoma".)

This syndrome can also be caused by lacrimal gland infiltration due to sarcoidosis, lymphoma, graft versus host disease, and episcleritis. Other causes include contact lens use, which is associated with reduced corneal sensitivity and subsequent reduced reflex sensory tear secretion [20], and diabetes mellitus [21]. (See "Complications of contact lenses" and "Episcleritis".)

Increased evaporative loss — Excessive water loss from the ocular surface leads to tear film instability and a cycle of tear hyperosmolarity and lacrimal functional unit inflammation. Increased tear evaporation is most commonly caused by meibomian gland dysfunction, also known as posterior blepharitis, in which the accessory lacrimal glands responsible for the lipid component of the tear film are dysfunctional [19]. In a normally functioning eye, the nature of the mucin allows even spreading of the tear film to form a membrane, and the lipid layer provides a barrier to minimize evaporation of tears [22]. Abnormalities of the lipid layer are associated with a higher rate of tear film evaporation [23].

Structural abnormalities of eyelid position or decreased blink function also increase evaporation of the tear film by increasing the area or the time of tear film exposure [19,24]. Lastly, topical medicated or preserved eye drop use, chronic contact lens wear, and ocular allergy syndromes can cause ocular surface irritation and increased tear film evaporation [19,24].

SYMPTOMS — Most patients will present with symptoms of chronic eye irritation associated with mild to moderate discomfort [25]. However, there is considerable variability in patient-reported symptoms and clinically measurable signs over time, as well as a recognized lack of correlation between these symptoms and signs [24,26-28].

Common eye complaints include:

Dryness

Red eyes

General irritation

Gritty sensation

Burning sensation

Foreign body sensation

Paradoxical excessive tearing

Light sensitivity

Blurred vision

Inciting or exacerbating causes include medications, windy conditions, cold weather, low-humidity environment, extended time spent looking at screens, and time of day.

The blurred vision associated with DED tends to be quite variable. Since the tear film is the first layer encountered by light rays as they enter the eye, an irregular tear film can degrade the quality of the image that is received by the retina. The visual impairment associated with DED is usually temporary and often improves with treatment of the condition [29,30]. Rarely, in severe DED conditions, permanent damage to visual acuity can occur from corneal scarring or ulceration.

If ocular complaints are accompanied by mouth dryness and other systemic complaints, an evaluation for Sjögren's syndrome should be performed. (See "Diagnosis and classification of Sjögren's syndrome".)

Questionnaires — Due to the variability of findings on clinical evaluation of dry eye disease (DED), some clinicians base their assessment of DED on the results of validated questionnaires [31]. These can also be used for monitoring DED and can be useful for standardizing the identification and classification of DED [32].

Some of the more widely available questionnaires that are used specifically for the evaluation of DED symptoms include:

Ocular Surface Disease Index (OSDI) – Twelve-item questionnaire validated in patients with DED [33]. The OSDI can be useful clinically, particularly in patients with more severe symptoms, to monitor the response to therapy and variability in symptoms over time.

Dry Eye Questionnaire (DEQ-5) – Five-item questionnaire reduced from the Dry Eye Questionnaire and validated to determine DED symptom severity [34].

Impact of Dry Eye on Everyday Life (IDEEL) – Fifty-seven questions in three modules validated in patients with DED [35].

Salisbury Eye Evaluation Questionnaire (SEE) – Six-item questionnaire used in self-reported, population-based prevalence surveys to determine visual impairment among older adult subjects [36].

DIAGNOSIS — The diagnosis of dry eye disease (DED) is based on characteristic patient symptoms and supporting findings on the physical examination, both of which can vary considerably in intensity over time and under different environmental conditions. Potential supportive findings on physical examination include:

Conjunctival injection, usually symmetric in both eyes (picture 1).

Breakdown of ocular surface, and corneal scarring (picture 2A-B).

Excessive reflex tearing from irritation due to dryness, which can paradoxically be a sign of DED.

Blepharitis, often visible as erythematous or irritated eyelid edges (picture 3A-B).

Malposition of the eyelids (inward or outward turning, also called entropion and ectropion, respectively) (picture 4 and picture 5).

Reduced blink rate. Normal blink rate varies by environment and activity but is generally in the range of 5 to 26 blinks per minute [37].

Visual impairment, with visual acuity assessed in each eye separately. This should include evaluation as to whether acuity improves with increased blink rate or use of lubricating eye drops.

Differential diagnosis and coexisting conditions — Other conditions that can cause similar symptoms to DED include:

Viral conjunctivitis – DED can be confused with "pink eye." A careful patient history to elicit course of recent and abrupt onset of symptoms, any recent illnesses or sick contacts, and presence of lymphadenopathy can help to distinguish the diagnosis. (See "Conjunctivitis".)

Other microbial infections – Some ocular infections can begin with an indolent course of symptoms similar to DED. Referral to an ophthalmologist should be considered for any patients at high risk for ocular infections (eg, contact lens wearer, history of diabetes mellitus), particularly those with signs of an infectious process on physical examination (eg, unilateral conjunctival injection, purulent drainage).

Coexisting disorders include:

Blepharitis/Meibomian gland dysfunction – Posterior blepharitis often coexists with DED and may require specific treatments, including warm compresses and patient education on eyelid hygiene. (See "Blepharitis".)

Ocular allergies – Allergic conjunctivitis can also coexist with DED. Symptoms of itching will often be the primary complaint. The allergen should be promptly identified and avoided. (See "Allergic conjunctivitis: Clinical manifestations and diagnosis".)

INITIAL TREATMENT — Treatment for dry eye disease (DED) is aimed at improving symptoms by increasing or supplementing tear production, slowing tear evaporation, reducing tear resorption, or reducing ocular surface inflammation. In addition to symptomatic relief, treatment with artificial tears may improve visual acuity and prevent against ocular damage [7,38,39].

First line treatments — The first line of treatment in patients complaining of DED are:

Tear supplementation

Environmental coping strategies

Amelioration of eyelid abnormalities including blepharitis (see "Blepharitis")

Application of warm compresses (to soften secretions in obstructed meibomian gland excretory ducts)

Discontinuation of systemic or ocular medications that can contribute to dryness, if possible (see 'Risk factors' above)

Patients who do not obtain adequate relief from tear supplementation or environmental adjustment should be referred to an ophthalmologist.

Artificial tears — Artificial tears generally include cellulose to maintain viscosity, a spreading agent such as polyethylene glycol or polyvinyl alcohol to prevent evaporation, and a preservative to prevent contamination. Available without a prescription, artificial tears come in liquid, gel, and ointment forms. Preservative-free forms of these supplements are often recommended as some individuals with DED will have inflammatory reactions to the preservatives [40]. However, these are often expensive, single-use formulations.

Drops – A reasonable starting dose is one drop in each eye, four times per day. Patients often begin to notice improvement within a few days of initiating treatment but may take up to three to four weeks to note a significant change in their symptoms. Some patients may benefit from viewing an online video (eg, YouTube) for a demonstration of eyedrop administration methods.

If individuals remain symptomatic, the frequency can be increased to as frequently as every hour. If used more often than four to six times per day, a preservative-free formulation is preferable to minimize the potential for toxicity [41].

Gels and ointments – Higher-viscosity artificial tear gels and ointments are also commercially available and can be used if patients feel that the eye drops are not providing enough symptomatic relief. Patients should be warned that the gels, and especially ointments, can blur vision temporarily and are often best used at bedtime.

Response to therapy can be monitored subjectively or with standardized questionnaires (see 'Questionnaires' above). Chronic treatment is usually needed, unless a specific inciting factor can be eliminated.

Randomized trials of efficacy are mostly limited due to sample size, lack of an adequate control group, lack of clear diagnostic criteria, and non-standardized outcomes [42-45]. As laser-assisted in situ keratomileusis (LASIK) is a refractive procedure that causes dry eyes, in part due to decreased postoperative corneal sensation, LASIK serves as a model for assessing treatment of DED. Artificial tears given to postoperative LASIK patients appear to improve DED symptoms compared with placebo [46]. Issues related to DED and LASIK are discussed separately. (See "Laser refractive surgery".)

Environmental strategies — Environmental coping strategies address the importance of environmental causes that could be contributing to or even causing DED symptoms. One important strategy includes frequent blinking, especially during visually attentive tasks such as reading or computer use. The patient should also be urged to minimize exposure to air conditioning or heating. Humidifiers are useful in the bedroom, office, or any space where the patient spends a significant amount of time.

Physical barriers around the eyes or "moisture chambers" are recommended to protect the humidity of the local environment around the eyes. Moisture chambers can be purchased and fitted to current glasses in select optical shops by trained opticians (picture 6A-B).

Indications for referral — In most patients, first-line treatment can be initiated by the primary care provider. However, initial referral to an ophthalmologist is appropriate for patients with neuropathy (including diabetic neuropathy), as they may have reduced sensation and be unaware of severe dryness, which may cause visual disturbance or ocular surface damage if not treated. We also suggest initial referral to an ophthalmologist if the diagnosis is in question or if the patient has severe pain or associated visual loss, or abnormal blinking or inability to close their eyes completely [47]. (See 'Ophthalmology evaluation and treatment' below.)

OPHTHALMOLOGY EVALUATION AND TREATMENT

Evaluation — The ophthalmologist will perform a thorough slit lamp examination along with other testing to assess the status of the patient's lacrimal functional unit to determine the severity of dry eye disease (DED) and possible etiologies. Evaluation includes:

Extent and pattern of conjunctival injection.

Eyelid health – Any eyelid or punctal malpositions are noted as they can lead to DED and often can be surgically repaired. Careful evaluation for meibomian gland dysfunction (posterior blepharitis) is performed.

Ocular surface staining – Fluorescein is used to stain for areas of discontinuity in the epithelial surface of the cornea (picture 7). Lissamine green and Rose Bengal are used to stain areas of devitalized epithelium in the cornea and conjunctiva.

Tear break-up time – Measured with fluorescein stain in the eye to determine tear film stability. The patient is instructed not to blink and the tear film is observed through the slit lamp. If the smooth, stained green tear film layer begins to develop blue gaps in less than 10 seconds, the patient's tear film is considered abnormal.

Schirmer test – Assessed by quantifying the number of tears produced by each eye. Small strips of filter paper are placed in the lower eyelids of each eye, either with or without prior instillation of anesthetic eye drops. Results are measured in millimeters of tears collected over a five-minute time period. This test is often used in the clinical setting but provides extremely variable results [26].

Corneal sensation – Objectively measured with a variety of techniques to provide information about ocular surface and possibly systemic associations of DED.

Tear hyperosmolarity [48,49].

Ocular surface inflammation (eg, matrix metalloproteinase 9 as a marker of ocular surface inflammation) [50,51].

Tear film measurements – In-office imaging instruments can be used to more objectively measure the ocular surface and the tear film, including tear meniscus height, tear film stability, blink dynamics, and meibography of the eyelids.

Treatment — The choice of topical treatments is usually guided by medication cost and insurance coverage.

Topical cyclosporine — Topical cyclosporine is a safe and well-tolerated immunosuppressive agent, although it is not clear that it leads to a clinically important benefit in the treatment of DED [52,53]. The multiple randomized trials of topical cyclosporine indicating its efficacy vary greatly by dose of cyclosporine, the comparator control used (ie, active comparator or no treatment), and the endpoint reported; thus, the degree of benefit afforded by use of this agent remains uncertain.

Although not universally beneficial, there appears to be a subset of patients who do respond favorably to this treatment, but there are no good predictive models available to guide clinical decision-making. In the author’s anecdotal experience, patients with a systemic condition associated with inflammation, including graft-versus-host disease, tend to have the highest likelihood of response to cyclosporine drops [54].

In such patients, a 0.05% emulsion and a 0.09% solution of cyclosporine are available for treatment of DED. It may take up to six weeks or longer of treatment to achieve noticeable improvement of dryness. In some patients, cyclosporine can result in long-term resolution of DED symptoms, as shown in one case series describing eight such patients, five of whom represented about 4 percent of all cyclosporine-treated patients with chronic DED in one clinical practice [55].

Serum cyclosporine concentrations have been undetectable or negligible with topical use, and no systemic toxicity has been reported. Cyclosporine can cause an occasional, temporary burning sensation in the eye. Another important limiting factor is high cost [38].

As patients may have other concurrent problems such as infection leading to eye irritation, they should have a complete ophthalmological examination prior to receiving cyclosporine.

Topical lifitegrast — A topical eye drop formulation, lifitegrast 5.0%, an integrin antagonist, is used twice a day and has side effects of eye irritation or discomfort and an associated bad taste in approximately 25 percent of users [56]. In randomized trials, lifitegrast improved DED signs and symptoms in patients with mild to moderate and moderate to severe symptoms [56-60].

The prescription and monitoring of response to this agent should be done by an ophthalmologist.

Intranasal varenicline — A preservative-free nasal spray formulation of varenicline, a nicotinic acetylcholine receptor agonist, has been approved by the US Food and Drug Administration (FDA) for the treatment of dry eyes. The suspected mechanism of action is by activating the trigeminal parasympathetic pathway to stimulate natural tear production. In a trial conducted among adults with DED, varenicline use resulted in an increase in tear production, as measured by Schirmer test, after four weeks of twice-daily dosing compared with placebo (vehicle) [61]. The most common reported adverse events were sneezing, cough, and throat irritation.

Other — Although several other treatments are available for DED, they are not in common use and should only be used as an adjunctive treatment by eye specialists.

Topical glucocorticoids – Low-dose topical glucocorticoid eye drops can help to relieve symptoms and signs of DED [62,63] and are useful on a short-term basis. As these drops can have significant side effects with continued use, including cataracts and glaucoma, glucocorticoid eye drops should be used with caution and only be prescribed by an ophthalmologist for this indication.

Punctal occlusion – Either temporary punctal plugs or permanent cauterization of the puncta can be performed in an attempt to reduce the rate of tear drainage from the ocular surface and thereby possibly improve the signs and symptoms of DED [64].

Autologous serum tears – The serum of a patient's blood can be formulated into eye drops. Autologous serum tears may improve DED symptoms [65,66], but there is not strong evidence for long-term or significant benefit over artificial tears [67]. Access to these eye drops and cost are barriers to its use.

Tear stimulation – Systemic pilocarpine (a cholinergic agonist) has been found to improve DED symptoms in patients, most commonly those with Sjögren's syndrome, but is associated with systemic side effects in a significant portion of patients [68]. Other tear stimulation agents, including those for topical use, are being explored as potential treatments for DED [69].

Omega-3 fatty acids – Trials of oral omega-3 fatty acids for DED have shown mixed results, with a large multicenter clinical trial showing no additional benefit of omega-3 fatty acid supplementation over placebo in the improvement of DED signs and symptoms [70-74].

Oral antioxidants – Small randomized trials have shown some efficacy of oral antioxidants in the treatment of DED [75,76]. As an example, in a blinded, placebo-controlled cross-over trial of 24 DED patients, those randomly assigned an antioxidant combination (vitamins E, B2, C, zinc and selenium) compared with placebo had improved tear break-up times, Schirmer scores, and clinical symptoms, including burning, itching, and redness [75].

Scleral contact lenses – In patients with severe DED, large-diameter contact lenses can be used to help retain a tear reservoir over the ocular surface [77]. These types of contact lenses require a specialized fitting by an experienced contact lens practitioner.

Acupuncture – Small studies have shown some improvement in DED signs and symptoms following acupuncture therapy [78,79]. Acupuncture is discussed in detail separately.

Surgery – Eyelid abnormalities should be surgically corrected to realign and maintain normal lid architecture. Surgery can also be performed on structurally normal eyelids to reduce the ocular surface area and thus reduce tear evaporation.

Investigational – Diquafosol [80-82] and rebamipide [83-85] eye drops have also shown promise in improving DED.

INFORMATION FOR PATIENTS — UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5th to 6th grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10th to 12th grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.

Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)

Basics topic (see "Patient education: Dry eye (The Basics)")

SUMMARY AND RECOMMENDATIONS

Pathophysiology – Dry eye disease (DED) is a multifactorial disease of the tears and ocular surface that can result in ocular discomfort and visual impairment. DED is generally due to both decreased tear production and/or excessive evaporative loss. (See 'Pathophysiology' above.)

Clinical manifestations – Most patients present with symptoms of chronic eye irritation, such as eye dryness, red eyes, and burning. However, there is considerable variability in patient-reported symptoms over time. (See 'Clinical significance' above.)

Diagnosis – The diagnosis is based primarily on patient symptoms and supportive findings of DED from examination. Common findings include conjunctival injection and reduced blink rate. Some patients may have paradoxical excess reflex tearing. (See 'Diagnosis' above.)

Initial treatment – We suggest initial treatment with artificial tears for all patients with dry eye disease (Grade 2C). This is particularly important in patients who have reduced ocular sensation, such as those with neuropathy (including diabetic neuropathy), who may be unaware of severe dryness, which may cause visual disturbance or ocular surface damage if not treated. In addition to symptomatic relief, artificial tears may improve visual acuity and prevent against ocular damage.

When appropriate, environmental strategies should also be undertaken, including discussing the importance of frequent blinking and minimizing exposure to air conditioning or heating. (See 'Initial treatment' above.)

Indications for referral – Referral to an ophthalmologist is appropriate for patients with neuropathy (including diabetic neuropathy), those in whom the diagnosis is in question, patients with severe pain or associated visual loss, or those with abnormal blinking or inability to close their eyes completely. (See 'Indications for referral' above.)

Further treatment – Other treatment options include topical cyclosporine, other topical medications, oral medications, scleral contact lenses, punctal occlusion, and surgery. (See 'Treatment' above.)

  1. Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf 2017; 15:276.
  2. Stapleton F, Alves M, Bunya VY, et al. TFOS DEWS II Epidemiology Report. Ocul Surf 2017; 15:334.
  3. Farrand KF, Fridman M, Stillman IÖ, Schaumberg DA. Prevalence of Diagnosed Dry Eye Disease in the United States Among Adults Aged 18 Years and Older. Am J Ophthalmol 2017; 182:90.
  4. Paulsen AJ, Cruickshanks KJ, Fischer ME, et al. Dry eye in the beaver dam offspring study: prevalence, risk factors, and health-related quality of life. Am J Ophthalmol 2014; 157:799.
  5. Santaella RM, Fraunfelder FW. Ocular adverse effects associated with systemic medications : recognition and management. Drugs 2007; 67:75.
  6. Jaenen N, Baudouin C, Pouliquen P, et al. Ocular symptoms and signs with preserved and preservative-free glaucoma medications. Eur J Ophthalmol 2007; 17:341.
  7. Gilbard JP. The diagnosis and management of dry eyes. Otolaryngol Clin North Am 2005; 38:871.
  8. Latkany R. Dry eyes: etiology and management. Curr Opin Ophthalmol 2008; 19:287.
  9. Pflugfelder SC. Prevalence, burden, and pharmacoeconomics of dry eye disease. Am J Manag Care 2008; 14:S102.
  10. Schiffman RM, Walt JG, Jacobsen G, et al. Utility assessment among patients with dry eye disease. Ophthalmology 2003; 110:1412.
  11. Buchholz P, Steeds CS, Stern LS, et al. Utility assessment to measure the impact of dry eye disease. Ocul Surf 2006; 4:155.
  12. Reddy P, Grad O, Rajagopalan K. The economic burden of dry eye: a conceptual framework and preliminary assessment. Cornea 2004; 23:751.
  13. Stern ME, Beuerman RW, Fox RI, et al. The pathology of dry eye: the interaction between the ocular surface and lacrimal glands. Cornea 1998; 17:584.
  14. Belmonte C, Acosta MC, Gallar J. Neural basis of sensation in intact and injured corneas. Exp Eye Res 2004; 78:513.
  15. Belmonte C, Nichols JJ, Cox SM, et al. TFOS DEWS II pain and sensation report. Ocul Surf 2017; 15:404.
  16. Li DQ, Chen Z, Song XJ, et al. Stimulation of matrix metalloproteinases by hyperosmolarity via a JNK pathway in human corneal epithelial cells. Invest Ophthalmol Vis Sci 2004; 45:4302.
  17. Botsios C, Furlan A, Ostuni P, et al. Elderly onset of primary Sjögren's syndrome: clinical manifestations, serological features and oral/ocular diagnostic tests. Comparison with adult and young onset of the disease in a cohort of 336 Italian patients. Joint Bone Spine 2011; 78:171.
  18. Damato BE, Allan D, Murray SB, Lee WR. Senile atrophy of the human lacrimal gland: the contribution of chronic inflammatory disease. Br J Ophthalmol 1984; 68:674.
  19. The definition and classification of dry eye disease: report of the Definition and Classification Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5:75.
  20. Gilbard JP, Gray KL, Rossi SR. A proposed mechanism for increased tear-film osmolarity in contact lens wearers. Am J Ophthalmol 1986; 102:505.
  21. Kaiserman I, Kaiserman N, Nakar S, Vinker S. Dry eye in diabetic patients. Am J Ophthalmol 2005; 139:498.
  22. Tsubota K. Tear dynamics and dry eye. Prog Retin Eye Res 1998; 17:565.
  23. Bron AJ, Tiffany JM, Gouveia SM, et al. Functional aspects of the tear film lipid layer. Exp Eye Res 2004; 78:347.
  24. Lemp MA. Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes. CLAO J 1995; 21:221.
  25. Satitpitakul V, Kheirkhah A, Crnej A, et al. Determinants of Ocular Pain Severity in Patients With Dry Eye Disease. Am J Ophthalmol 2017; 179:198.
  26. Nichols KK, Mitchell GL, Zadnik K. The repeatability of clinical measurements of dry eye. Cornea 2004; 23:272.
  27. Nichols KK, Nichols JJ, Mitchell GL. The lack of association between signs and symptoms in patients with dry eye disease. Cornea 2004; 23:762.
  28. Begley CG, Chalmers RL, Abetz L, et al. The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity. Invest Ophthalmol Vis Sci 2003; 44:4753.
  29. Montés-Micó R. Role of the tear film in the optical quality of the human eye. J Cataract Refract Surg 2007; 33:1631.
  30. Liu Z, Pflugfelder SC. Corneal surface regularity and the effect of artificial tears in aqueous tear deficiency. Ophthalmology 1999; 106:939.
  31. The epidemiology of dry eye disease: report of the Epidemiology Subcommittee of the International Dry Eye WorkShop (2007). Ocul Surf 2007; 5:93.
  32. Wolffsohn JS, Arita R, Chalmers R, et al. TFOS DEWS II Diagnostic Methodology report. Ocul Surf 2017; 15:539.
  33. Schiffman RM, Christianson MD, Jacobsen G, et al. Reliability and validity of the Ocular Surface Disease Index. Arch Ophthalmol 2000; 118:615.
  34. Chalmers RL, Begley CG, Caffery B. Validation of the 5-Item Dry Eye Questionnaire (DEQ-5): Discrimination across self-assessed severity and aqueous tear deficient dry eye diagnoses. Cont Lens Anterior Eye 2010; 33:55.
  35. Rajagopalan K, Abetz L, Mertzanis P, et al. Comparing the discriminative validity of two generic and one disease-specific health-related quality of life measures in a sample of patients with dry eye. Value Health 2005; 8:168.
  36. Rubin GS, West SK, Muñoz B, et al. A comprehensive assessment of visual impairment in a population of older Americans. The SEE Study. Salisbury Eye Evaluation Project. Invest Ophthalmol Vis Sci 1997; 38:557.
  37. Bentivoglio AR, Bressman SB, Cassetta E, et al. Analysis of blink rate patterns in normal subjects. Mov Disord 1997; 12:1028.
  38. Drugs for some common eye disorders. Treat Guidel Med Lett 2010; 8:1.
  39. Nilforoushan MR, Latkany RA, Speaker MG. Effect of artificial tears on visual acuity. Am J Ophthalmol 2005; 140:830.
  40. Laflamme MY, Swieca R. A comparative study of two preservative-free tear substitutes in the management of severe dry eye. Can J Ophthalmol 1988; 23:174.
  41. Jones L, Downie LE, Korb D, et al. TFOS DEWS II Management and Therapy Report. Ocul Surf 2017; 15:575.
  42. Willen CM, McGwin G, Liu B, et al. Efficacy of cyclosporine 0.05% ophthalmic emulsion in contact lens wearers with dry eyes. Eye Contact Lens 2008; 34:43.
  43. Huang FC, Tseng SH, Shih MH, Chen FK. Effect of artificial tears on corneal surface regularity, contrast sensitivity, and glare disability in dry eyes. Ophthalmology 2002; 109:1934.
  44. Bron AJ, Mangat H, Quinlan M, et al. Polyacrylic acid gel in patients with dry eyes: a randomised comparison with polyvinyl alcohol. Eur J Ophthalmol 1998; 8:81.
  45. Brodwall J, Alme G, Gedde-Dahl S, et al. A comparative study of polyacrylic acid (Viscotears) liquid gel versus polyvinylalcohol in the treatment of dry eyes. Acta Ophthalmol Scand 1997; 75:457.
  46. Lenton LM, Albietz JM. Effect of carmellose-based artificial tears on the ocular surface in eyes after laser in situ keratomileusis. J Refract Surg 1999; 15:S227.
  47. Sharma RA, Mather R. Five things to know about...dry eye disease. CMAJ 2014; 186:1090.
  48. Lemp MA, Bron AJ, Baudouin C, et al. Tear osmolarity in the diagnosis and management of dry eye disease. Am J Ophthalmol 2011; 151:792.
  49. Sullivan BD, Whitmer D, Nichols KK, et al. An objective approach to dry eye disease severity. Invest Ophthalmol Vis Sci 2010; 51:6125.
  50. Sambursky R, Davitt WF 3rd, Latkany R, et al. Sensitivity and specificity of a point-of-care matrix metalloproteinase 9 immunoassay for diagnosing inflammation related to dry eye. JAMA Ophthalmol 2013; 131:24.
  51. Messmer EM, von Lindenfels V, Garbe A, Kampik A. Matrix Metalloproteinase 9 Testing in Dry Eye Disease Using a Commercially Available Point-of-Care Immunoassay. Ophthalmology 2016; 123:2300.
  52. Sacchetti M, Mantelli F, Lambiase A, et al. Systematic review of randomised clinical trials on topical ciclosporin A for the treatment of dry eye disease. Br J Ophthalmol 2014; 98:1016.
  53. de Paiva CS, Pflugfelder SC, Ng SM, Akpek EK. Topical cyclosporine A therapy for dry eye syndrome. Cochrane Database Syst Rev 2019; 9:CD010051.
  54. Malta JB, Soong HK, Shtein RM, et al. Treatment of ocular graft-versus-host disease with topical cyclosporine 0.05%. Cornea 2010; 29:1392.
  55. Wilson SE, Perry HD. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology 2007; 114:76.
  56. Donnenfeld ED, Karpecki PM, Majmudar PA, et al. Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study. Cornea 2016; 35:741.
  57. Sheppard JD, Torkildsen GL, Lonsdale JD, et al. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology 2014; 121:475.
  58. Tauber J, Karpecki P, Latkany R, et al. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study. Ophthalmology 2015; 122:2423.
  59. Semba CP, Torkildsen GL, Lonsdale JD, et al. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye. Am J Ophthalmol 2012; 153:1050.
  60. Holland EJ, Luchs J, Karpecki PM, et al. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3). Ophthalmology 2017; 124:53.
  61. Wirta D, Vollmer P, Paauw J, et al. Efficacy and Safety of OC-01 (Varenicline Solution) Nasal Spray on Signs and Symptoms of Dry Eye Disease: The ONSET-2 Phase 3 Randomized Trial. Ophthalmology 2022; 129:379.
  62. Avunduk AM, Avunduk MC, Varnell ED, Kaufman HE. The comparison of efficacies of topical corticosteroids and nonsteroidal anti-inflammatory drops on dry eye patients: a clinical and immunocytochemical study. Am J Ophthalmol 2003; 136:593.
  63. Pinto-Fraga J, López-Miguel A, González-García MJ, et al. Topical Fluorometholone Protects the Ocular Surface of Dry Eye Patients from Desiccating Stress: A Randomized Controlled Clinical Trial. Ophthalmology 2016; 123:141.
  64. Ervin AM, Law A, Pucker AD. Punctal occlusion for dry eye syndrome. Cochrane Database Syst Rev 2017; 6:CD006775.
  65. Noble BA, Loh RS, MacLennan S, et al. Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease. Br J Ophthalmol 2004; 88:647.
  66. Soni NG, Jeng BH. Blood-derived topical therapy for ocular surface diseases. Br J Ophthalmol 2016; 100:22.
  67. Pan Q, Angelina A, Zambrano A, et al. Autologous serum eye drops for dry eye. Cochrane Database Syst Rev 2013; :CD009327.
  68. Tsifetaki N, Kitsos G, Paschides CA, et al. Oral pilocarpine for the treatment of ocular symptoms in patients with Sjögren's syndrome: a randomised 12 week controlled study. Ann Rheum Dis 2003; 62:1204.
  69. Tauber J, Davitt WF, Bokosky JE, et al. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye. Cornea 2004; 23:784.
  70. Kokke KH, Morris JA, Lawrenson JG. Oral omega-6 essential fatty acid treatment in contact lens associated dry eye. Cont Lens Anterior Eye 2008; 31:141.
  71. Wojtowicz JC, Butovich I, Uchiyama E, et al. Pilot, prospective, randomized, double-masked, placebo-controlled clinical trial of an omega-3 supplement for dry eye. Cornea 2011; 30:308.
  72. Kangari H, Eftekhari MH, Sardari S, et al. Short-term consumption of oral omega-3 and dry eye syndrome. Ophthalmology 2013; 120:2191.
  73. Bhargava R, Kumar P. Oral omega-3 fatty acid treatment for dry eye in contact lens wearers. Cornea 2015; 34:413.
  74. Dry Eye Assessment and Management Study Research Group, Asbell PA, Maguire MG, et al. n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease. N Engl J Med 2018; 378:1681.
  75. Drouault-Holowacz S, Bieuvelet S, Burckel A, et al. Antioxidants intake and dry eye syndrome: a crossover, placebo-controlled, randomized trial. Eur J Ophthalmol 2009; 19:337.
  76. Blades KJ, Patel S, Aidoo KE. Oral antioxidant therapy for marginal dry eye. Eur J Clin Nutr 2001; 55:589.
  77. Jacobs DS, Rosenthal P. Boston scleral lens prosthetic device for treatment of severe dry eye in chronic graft-versus-host disease. Cornea 2007; 26:1195.
  78. Tseng KL, Liu HJ, Tso KY, et al. A clinical study of acupuncture and SSP (silver spike point) electro-therapy for dry eye syndrome. Am J Chin Med 2006; 34:197.
  79. Grönlund MA, Stenevi U, Lundeberg T. Acupuncture treatment in patients with keratoconjunctivitis sicca: a pilot study. Acta Ophthalmol Scand 2004; 82:283.
  80. Shigeyasu C, Hirano S, Akune Y, Yamada M. Diquafosol Tetrasodium Increases the Concentration of Mucin-like Substances in Tears of Healthy Human Subjects. Curr Eye Res 2015; 40:878.
  81. Gong L, Sun X, Ma Z, et al. A randomised, parallel-group comparison study of diquafosol ophthalmic solution in patients with dry eye in China and Singapore. Br J Ophthalmol 2015; 99:903.
  82. Yamaguchi M, Nishijima T, Shimazaki J, et al. Clinical usefulness of diquafosol for real-world dry eye patients: a prospective, open-label, non-interventional, observational study. Adv Ther 2014; 31:1169.
  83. Ueda K, Matsumiya W, Otsuka K, et al. Effectiveness and relevant factors of 2% rebamipide ophthalmic suspension treatment in dry eye. BMC Ophthalmol 2015; 15:58.
  84. Arimoto A, Kitagawa K, Mita N, et al. Effect of rebamipide ophthalmic suspension on signs and symptoms of keratoconjunctivitis sicca in Sjögren syndrome patients with or without punctal occlusions. Cornea 2014; 33:806.
  85. Kinoshita S, Awamura S, Nakamichi N, et al. A multicenter, open-label, 52-week study of 2% rebamipide (OPC-12759) ophthalmic suspension in patients with dry eye. Am J Ophthalmol 2014; 157:576.
Topic 6894 Version 51.0

References